GlaxoSmithKline Pharmaceuticals Limited

BSE:500660 Stock Report

Market Cap: ₹451.3b

GlaxoSmithKline Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

GlaxoSmithKline Pharmaceuticals has been growing earnings at an average annual rate of 13.7%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 1.4% per year. GlaxoSmithKline Pharmaceuticals's return on equity is 33.2%, and it has net margins of 17.1%.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate1.4%
Return on equity33.2%
Net Margin17.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How GlaxoSmithKline Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:500660 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2434,5375,9007,3580
31 Dec 2333,1145,2897,1160
30 Sep 2333,0846,4787,2330
30 Jun 2332,6836,2377,2000
31 Mar 2332,5176,0767,0620
31 Dec 2232,7394,1957,1630
30 Sep 2232,8753,9407,0570
30 Jun 2233,0483,8977,2380
31 Mar 2232,7803,8087,3970
31 Dec 2134,8615,1007,5210
30 Sep 2134,7084,9627,6890
30 Jun 2133,4033,6847,6290
31 Mar 2129,2562,8736,8580
31 Dec 2031,6094,8197,5230
30 Sep 2030,823-3,3587,5980
30 Jun 2030,8509057,5330
31 Mar 2032,2449327,7410
31 Dec 1931,9941,0197,5790
30 Sep 1932,4618,7687,1680
30 Jun 1931,8044,7497,0880
31 Mar 1931,2814,4546,9250
31 Mar 1828,7153,5076,4020
31 Mar 1729,0853,3686,0290
31 Mar 1628,3793,7615,6010
31 Mar 1526,3843,8115,2350
31 Dec 1325,5974,8176,6050

Quality Earnings: 500660 has high quality earnings.

Growing Profit Margin: 500660's current net profit margins (17.1%) are lower than last year (18.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 500660's earnings have grown by 13.7% per year over the past 5 years.

Accelerating Growth: 500660's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 500660 had negative earnings growth (-2.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18%).

Return on Equity

High ROE: 500660's Return on Equity (33.2%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.